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HABP2 germline variants are uncommon in
familial nonmedullary thyroid cancer
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Abstract
Background: The genetic basis of nonsyndromic familial nonmedullary thyroid cancer (FNMTC) is poorly understood.
A recent study identified HABP2 as a tumor suppressor gene and identified a germline variant (G534E) in an extended
FNMTC kindred. The relevance of this to other FNMTC kindreds is uncertain.
Methods: Sanger sequencing was performed on peripheral blood DNA from probands from 37 Australian FNMTC
kindreds to detect the G534E variant. Whole exome data from 59 participants from 20 kindreds were examined for
mutations in HABP2 and the thyroid cancer susceptibility genes SRGAP1, NKX2-1, SRRM2 and FOXE1. The population
prevalence of the G534E variant in HABP2 was examined in two independent cohorts.
Results: Heterozygosity for the G534E variant in HABP2 was found in 1 of 37 probands (2.7 %), but did not cosegregate
with disease in this kindred, being absent in the proband’s affected sister. From whole exome data, pathogenic
mutations were not identified in HABP2, SRGAP1, NKX2-1, SRRM2 or FOXE1. Heterozygosity for the G534E variant in
HABP2 was present in 7.6 % of Busselton Health Study participants (N = 4634, unknown disease status) and 9.3 %
of TwinsUK participants (N = 1195, no history of thyroid cancer).
Conclusions: The G534E variant in HABP2 does not account for the familial nature of NMTC in Australian kindreds,
and is common in the general population. Further research is required to elucidate the genetic basis of nonsyndromic
FNMTC.
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Background
Thyroid cancer is one of the most common endocrine
malignancies, accounting for 95 % of malignancies in
endocrine organs [1]. The incidence of thyroid cancer is
increasing worldwide, and in the US alone has almost
tripled in the last 30 years [1, 2]. Nonmedullary thyroid
cancers (NMTC) account for over 95 % of thyroid
cancers [3]. These cancers are of follicular origin and are
comprised of papillary (PTC) (accounting for 85 % of
NMTC), follicular (11 %), Hürthle cell (3 %) and
anaplastic histotypes (1 %). The remaining 5 % of thyroid
cancers, medullary thyroid cancer (MTC), arise from the
parafollicular C cells [4].
NMTC shows significant heritability, with an 8 to
10-fold increased risk in first-degree relatives of affected
individuals [5]. Nonsyndromic familial nonmedullary
thyroid cancer (FNMTC) is thought to account for
approximately 3.5–10 % of all NMTC [6]. It is defined
by the presence of thyroid cancer of follicular cell origin
in 2 or more first-degree relatives, in the absence of a
recognized familial cancer syndrome (such as Cowden
syndrome or familial adenomatous polyposis) [7]. Both
familial and sporadic NMTC are more common in
women than men [8].
Whilst it seems clear that there is a hereditary basis to
nonsyndromic FNMTC, until recently no specific genetic
mutation has been discovered with a confirmed role in eti-
ology [9]. Studies investigating the basis of FNMTC have
identified 4 susceptibility genes, SRGAP1 (SLIT-ROBO
Rho GTPase Activating Protein 1), FOXE1 (Forkhead Box
E1), SRRM2 (Serine/Arginine Repetitive Matrix 2) and
NKX2.1 (NK2 Homeobox 1) [10–12]. A number of
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susceptibility candidate chromosomal loci were also iden-
tified, at 1q21, 6q22, 8p23.1-p22 and 8q24 [13]. It has
been suggested that FNMTC is an autosomal dominant
condition with incomplete penetrance and variable ex-
pressivity, but the exact mode of inheritance remains un-
known [14]. Alternatively, FNMTC may be a polygenic
disease caused by a low-to-moderate number of low-
penetrant alleles [5].
In a recent study, Gara et al. identified HABP2
(Hyaluronan Binding Protein 2) as a novel causative
gene in FNMTC. A single G→A substitution (G534E)
in exon 13 was associated with FNMTC in a kindred
with 7 affected individuals [15]. Using expression
studies and cell transformation assays, the study pro-
vided evidence that HABP2 is a tumor-suppressor gene.
The G534E variant was also found in 19 of 423 (4.7 %)
multi-ethnic patients with PTC from the Cancer
Genome Atlas (TCGA), as compared with 0.7 % of indi-
viduals with unknown disease status.
In subsequent editorial correspondence, however, it was
reported that the G534E variant in HABP2 was not de-
tected in 12 FNMTC kindreds or 217 sporadic PTC cases
from China [16], and it was suggested that in some
populations, the prevalence of the G543E variant was
much higher than 0.7 %, and as high as 3–5.7 % [17–19].
Several additional studies have now been published.
Tomsic et al. identified the G534E variant in 6.1 % of
familial cases, 8.0 % of sporadic cases and 8.7 % of con-
trols, and found that the variant did not cosegregate with
NMTC in several kindreds [20]. In a study of 2105 NMTC
cases from the British Isles, the frequency of the variant
was 4.2 % in cases and 4.6 % in controls [21]. In a study
from Saudi Arabia, Alzahrani et al. found no association
between the variant and familial or sporadic NMTC com-
pared with controls [22]. These studies, therefore, do not
support an association between the variant and NMTC. In
contrast, in a study from China, Zhang et al. identified the
variant in 6 affected subjects from 4 kindreds, consistent
with HABP2 being a FNMTC susceptibility gene [23].
The association between this variant and NMTC is
therefore somewhat controversial. To address this, we
investigated a collection of 37 FNMTC kindreds for the
presence of this variant using Sanger sequencing. We ex-
amined whole exome data from a subset of kindreds for
other pathogenic missense variants in HABP2 and for
mutations in SRGAP1, NKX2-1, SRRM2 and FOXE1. We
also determined the population prevalence of the G543E
variant in HABP2 in two independent cohorts.
Methods
Starting in November 2009, we recruited affected and
unaffected members of kindreds to a study of the genetic
basis of nonsyndromic FNMTC, initially using a candi-
date gene approach and subsequently using whole
exome sequencing. The setting of the study was a
tertiary referral center in Western Australia. Probands
and kindreds were referred by clinicians (endocrinolo-
gists, surgeons and nuclear medicine physicians) and
also identified from the Familial Cancer Registry of Gen-
etic Services of Western Australia. DNA was extracted
from peripheral whole blood using QIAGEN QIAamp
DNA Blood mini or midi kits (QIAGEN Pty, Chadstone,
Victoria, Australia) according to manufacturer's instruc-
tions. Quantification was performed using the Nano-
drop2000. Sanger sequencing of exon 13 of HABP2
(including the G534E variant) was performed on DNA
from probands from each kindred using primers as
described by Gara et al. [15] Sanger sequencing was
performed by the Australian Genome Research Facility
(AGRF;www.agrf.org.au) and data analyzed using
Geneious (Biomatters Ltd., Auckland, New Zealand).
Whole exome capture and sequencing was performed by
AGRF and by Lotterywest State Biomedical Facility
Genomics (Perth, Western Australia) using Illumina
HiSeq2000 and Applied Biosystems 5500 SOLiD sys-
tems. Exome capture was performed using SureSelect
Human All Exon V5 + UTRs, TargetSeq Exome Enrich-
ment System and TruSeq Exome Enrichment kit. We
captured and sequenced coding regions to a mean depth
of 68.7× which was sufficient to call variants at ~98 % of
each targeted exome. An average of 87,245,482 reads
were generated per affected individual as paired end,
100 bp reads. The exome data were annotated using
ANNOVAR [24] and examined for pathogenic missense,
splice-site, nonsense and start-gained variants in the
HABP2 gene, as well as novel and previously identified
variants in the SRGAP1, NKX2-1, SRRM2 and FOXE1
genes, using Varsifter software [25]. The predictive tools
Polyphen-2, SIFT and MutationTaster were used to
determine pathogenicity of detected variants and Minor
allele frequency data from the 1000 Genomes Project
was used to determine population frequency.
The population frequency of the G534E variant was
estimated using deeply imputed genome wide association
(GWA) data from 4634 participants in the 1994-5
Busselton Health Study (www.bpmri.org.au) a community-
based, mainly White cohort from Western Australia.
Genotyping was performed using the Illumina 610Q and
660W arrays, with results imputed to the 1000 Genomes
(Build 37) reference panel, as previously described [26].
The frequency of the variant by direct genotyping was as
determined from next-generation sequence data from 1195
participants in the TwinsUK cohort (www.twinsuk.ac.uk).
These participants were euthyroid, with no history of
thyroid surgery or thyroxine treatment. Next-generation
sequencing was performed using the Illumina HiSeq
platform and aligned to GRCh37 human reference
sequence as previously described [26].
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The study was approved by the Sir Charles Gairdner
Group Human Research Ethics Committee (trial no.
2009-128). Written informed consent was provided by
all participants.
Results
We recruited 109 participants from 37 kindreds with
nonsyndromic FNMTC to the study. The number of in-
dividuals with thyroid cancer ranged from 2 to 6 per
kindred; in 28 kindreds there were 2 affected individuals,
in 9 kindreds there were 3 or more affected individuals.
The ethnicity was Caucasian for 33 kindreds and Asian
for 4 kindreds (Table 1).
Sanger sequencing was performed on peripheral blood
DNA from probands from each kindred in order to de-
tect the G534E variant in HABP2. Heterozygosity for the
G534E variant was detected in a proband from a single
kindred (Fig. 1a). The pedigree is illustrated in Fig. 1b.
The proband was a white female who underwent facial
irradiation for acne at age 16, and presented in 1993 at
age 46 with bilateral thyroid nodules. Fine needle
aspiration biopsy from the right lobe of thyroid was con-
sistent with Hürthle cell neoplasm, and from the left
lobe was consistent with hemorrhage into a thyroid nod-
ule. Total thyroidectomy was performed. Histopathology
of the right lobe showed a 30 mm follicular variant of
PTC, a 20 mm hemorrhagic Hürthle cell adenoma and
two further small foci of PTC. In the left lobe, there
were multiple Hürthle cell adenomas up to 25 mm in
diameter and a further small focus of PTC. One of 2
excised lymph nodes contained metastatic PTC. Radio-
active iodine (3000 MBq) was administered, with no
evidence of distant metastases on the post-therapy scan
(stage T2N1MO). There has been no evidence of recur-
rence during follow-up. The proband’s son also has the
G534E variant. He has no significant medical history, but
has not yet been assessed clinically or sonographically for
thyroid neoplasia.
The proband’s affected sister underwent a right
hemithyroidectomy in 1985 at age 36 for a thyroid nodule.
Histopathology was of follicular adenoma, with an inci-
dental finding of a single focus of papillary microcancer.
At age 55 she developed a left sided thyroid nodule and
underwent completion thyroidectomy. Histopathology
revealed a 13 mm predominantly cystic PTC with an
additional 3mm focus of follicular variant of PTC (stage
T1NXMX). She did not receive radioiodine treatment and
there has been no evidence of recurrence during follow-
up. Sanger sequencing on this individual revealed wild
type results, without the G534E variant in HABP2.
The G534E variant in HABP2 was not found in pro-
bands from the remaining 36 kindreds by Sanger sequen-
cing. Whole exome sequencing data were available from
59 individuals (50 affected, 9 unaffected) from 20 FNMTC
kindreds, of which 7 kindreds had 2 affected individuals
and 13 kindreds had 3 or more affected individuals, and
were examined for the G534E variant and other patho-
genic missense variants in HABP2; none were identified.
The whole exome data were also examined for variants
previously reported as associated with NMTC in SRGAP1
(Q149H, R617C), FOXE1 (A248G), SRRM2 (S346F) and
NKX2.1 (A339V) and for novel pathogenic mutations in
these genes; none were identified in the kindreds.
The population frequency of the G534E variant was
determined from two independent cohorts. Of 4634
participants in the 1994-5 Busselton Health Study (with
unknown thyroid cancer status), 351 (7.6 %) were
heterozygous for the variant (from imputed genotypes),
whereas 4 were homozygous, giving a minor allele
frequency of 3.9 %. From directly genotyped next-
generation sequence data from 1195 participants in the
TwinsUK study who had no history of thyroid cancer or
other thyroid diseases, 111 (9.3 %) were heterozygous
for the variant and 1 individual was homozygous, giving
a minor allele frequency of 4.7 %.
Table 1 Characteristics of 37 FPTC probands
Characteristic Patients (N = 37)
Age at diagnosis (SD) 46.7 (15.9)
Female N (%) 27 (73.0 %)
Ethnicity
Caucasian 33 (89.2 %)
Asian 4 (10.8 %)
Histological subtype
Papillary 30 (81.1 %)
Papillary (follicular variant) 6 (16.2 %)
Papillary (tall cell variant) 1 (2.7 %)
Multifocal 25 (67.6 %)
TNM staginga
T1 N0 M0 10
T2 N0 M0 5
T3 N0 M0 1
T4 N0 M0
T1 N1 M0 5
T2 N1 M0 7
T3 N1 M0 5
T4 N1 M0 3
Staginga
I 23 (63.9 %)
II 3 (8.3 %)
III 6 (16.7 %)
IV 4 (11.1 %)
aAvailable for 36 probands. Detailed histopathology not available for one
proband who underwent surgery in 1983
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Discussion
This study examined the frequency of the recently iden-
tified G534E variant in HABP2 in a sample of FNMTC
kindreds. We identified the variant in only 1 of 37
kindreds (2.7 %). The proband in this kindred had un-
usual thyroid histopathology, with multiple Hürthle cell
adenomas as well as multifocal PTC. She had previously
undergone head and neck irradiation for acne, a well-
recognized risk factor for thyroid cancer, which occurs
in up to 31 % of individuals receiving this treatment
[27]. Her histopathology presumably reflects the exten-
sive mutagenic effects of ionizing radiation combined
with genetic predisposition to thyroid neoplasia. In this
kindred, the variant did not cosegregate with the disease,
being absent in her sibling, who had multifocal PTC.
There are two possible explanations for this. The sister
may represent a phenocopy, as thyroid cancer can affect
two members of the same family by chance or because
of shared environmental rather than genetic factors [28].
Alternatively, it may be that these two siblings share
pathogenic mutations in as yet unidentified susceptibility
genes.
The frequency of the G534E variant carriers in two
independent cohorts was 7.6 and 9.3 %, indicating that
this is in fact a common polymorphism, rather than a
rare variant. The frequency in the 37 probands was
somewhat lower (2.7 %), showing that this variant does
not explain the familial aggregation of NMTC in the kin-
dreds studied. Gara et al. reported the G534E mutation
in 4.7 % of a sample of patients with PTC from TCGA
[15], and our results are broadly consistent with that.
Gara et al. also provided evidence from functional stud-
ies that HABP2 is a tumor suppressor gene, and that the
G534E variant results in loss of function. It remains pos-
sible that the G534E variant in HABP2 is a susceptibility
locus for cancer, but further studies are required to de-
termine that. Other associations have been reported for
the G534E variant of HABP2 including thrombophilia,







Fig. 1 Panel a shows the sequence chromatogram of G534E variant in the proband and the reference sequence. Panel b shows the pedigree
with the HABP2 genotype for the G534E variant A/G (wild type is G/G). Squares denote male family members, circles female members, shaded
symbols affected members and slashes deceased members. *Head and neck irradiation age 16, PTC (T2N1M0) and multiple Hürthle cell
adenomas at age 46. ^Multifocal PTC at age 55
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carotid stenosis and venous thromboembolism [29, 30],
but neither the proband nor her son (who also carries
this variant) have hematological or vascular disorders.
We also examined whole exome data for other mis-
sense mutations in HABP2 and for variants which are
thought to play a role in FNMTC in the known suscepti-
bility genes, SRGAP1, SRRM2, FOXE1 and NKX2.1.
However, none of those genes had pathogenic variants
identified in our study. Thus, the genetic basis of
FNMTC in these kindreds remains to be determined.
Strengths of our study include the number of FNMTC
kindreds recruited, and the use of both whole exome
and Sanger sequencing to identify pathogenic mutations.
A limitation is that not all members of all kindreds have
undergone exome sequencing to date. Many of the
kindreds studied had only two affected members which,
as noted above, could occur by chance.
Conclusions
In conclusion, we report that the G534E variant in HABP2
is uncommon in FNMTC kindreds. Its frequency in general
population indicates that it is a common polymorphism,
and its role (if any) in the pathogenesis of thyroid cancer re-
mains to be determined. Therefore the clinical yield of
sequencing this variant in affected kindreds is likely to be
small. The genetic basis of nonsyndromic FNMTC remains
largely unknown, and more research is urgently required to
elucidate this. In the meantime, the management of
nonsyndromic FNMTC kindreds remains primarily clinical,
as genetic testing has a minimal contribution to offer.
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